Tag Archives: chimeric antigen receptors

July, 2017

13 July
FDA Committee Recommends Approval for Novartis’ CAR-T Cell Therapy for Acute Lymphoblastic Leukemia

Basel, July 12, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell …
Share

3 May
Bluebird Bio Licenses Delivery Technology to Novartis for Development of CAR-T Therapies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG. “bluebird bio is a pioneer in the field of lentiviral vector-based cell and gene therapy, and our partnerships and licensing agreements have …
Share

17 June
Baylor and Cell Medica Launch Next-Generation CAR-T Cancer Therapies Partnership

London, UK and Houston, TX – June 17, 2016 – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, announced today a ground-breaking co-development partnership with Baylor College of Medicine (Baylor) to develop next-generation technologies for engineering immune cells with enhanced functions for the …
Share